Autoimmune Diseases  >>  firategrast (SB683699)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
firategrast (SB683699) / GSK
NCT00548769: Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

Completed
1
37
Europe, RoW
Formulation A, firategrast (SB683699), Formulation B, Formulation C, Formulation D
GlaxoSmithKline
Multiple Sclerosis
11/07
11/07
NCT01424462: Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.

Completed
1
20
RoW
A, B, C, D
GlaxoSmithKline
Multiple Sclerosis, Relapsing-Remitting
07/10
07/10
NCT01416363: Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Completed
1
38
RoW
Firategrast immediate release tablet, Firategrast modified release tablet, Firategrast gastro-retentive solution
GlaxoSmithKline
Multiple Sclerosis, Relapsing-Remitting
09/11
09/11

Download Options